Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand for obesity and diabetes therapies globally and in India.

Christy Redican grew up in Connecticut, spending summers sailing and playing tennis. “I was a sun worshipper,” she said. “I did all the things you’re not supposed to do. I have fair skin, blonde hair ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...